148 related articles for article (PubMed ID: 36998343)
21. Pancreatic adverse events in patients treated with immune checkpoint inhibitors.
Hana C; Rehman T; Park K; Carracedo Uribe C; Aung PP; Hunis B; Salzberg M; Zikria J; Hussein A
JGH Open; 2023 Mar; 7(3):204-207. PubMed ID: 36968572
[TBL] [Abstract][Full Text] [Related]
22. Hepatobiliary and Pancreatic Adverse Events.
Zhang HC; Wang LS; Miller E
Adv Exp Med Biol; 2021; 1342():339-355. PubMed ID: 34972973
[TBL] [Abstract][Full Text] [Related]
23. Workup and Management of Immune-Mediated Hepatobiliary Pancreatic Toxicities That Develop During Immune Checkpoint Inhibitor Treatment.
Hsu C; Marshall JL; He AR
Oncologist; 2020 Feb; 25(2):105-111. PubMed ID: 32043797
[TBL] [Abstract][Full Text] [Related]
24. Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology Group.
Grimmelmann I; Momma M; Zimmer L; Hassel JC; Heinzerling L; Pföhler C; Loquai C; Ruini C; Utikal J; Thoms KM; Kähler KC; Eigentler T; Herbst RA; Meier F; Debus D; Berking C; Kochanek C; Ugurel S; Gutzmer R;
Eur J Cancer; 2021 May; 149():1-10. PubMed ID: 33812141
[TBL] [Abstract][Full Text] [Related]
25. Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis.
Mooradian MJ; Wang DY; Coromilas A; Lumish M; Chen T; Giobbie-Hurder A; Johnson DB; Sullivan RJ; Dougan M
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32414860
[TBL] [Abstract][Full Text] [Related]
26. A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil.
Jespersen MS; Fanø S; Stenør C; Møller AK
Eur Heart J Case Rep; 2021 Nov; 5(11):ytab342. PubMed ID: 34870082
[TBL] [Abstract][Full Text] [Related]
27. Role of Infliximab in Immune Checkpoint Inhibitor-Induced Pneumonitis.
Lai KA; Sheshadri A; Adrianza AM; Etchegaray M; Balachandran DD; Bashoura L; Shannon VR; Faiz SA
J Immunother Precis Oncol; 2020 Nov; 3(4):172-174. PubMed ID: 35665375
[TBL] [Abstract][Full Text] [Related]
28. Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management.
Shivaji UN; Jeffery L; Gui X; Smith SCL; Ahmad OF; Akbar A; Ghosh S; Iacucci M
Therap Adv Gastroenterol; 2019; 12():1756284819884196. PubMed ID: 31723355
[TBL] [Abstract][Full Text] [Related]
29. Acute Interstitial Nephritis and Checkpoint Inhibitor Therapy: Single Center Experience of Management and Drug Rechallenge.
Manohar S; Ghamrawi R; Chengappa M; Goksu BNB; Kottschade L; Finnes H; Dronca R; Leventakos K; Herrmann J; Herrmann SM
Kidney360; 2020 Jan; 1(1):16-24. PubMed ID: 35372854
[TBL] [Abstract][Full Text] [Related]
30. Management of Acute Pancreatitis Associated With Checkpoint Inhibitors.
Rogers BB; Cuddahy T; Zawislak C
J Adv Pract Oncol; 2020; 11(1):49-62. PubMed ID: 33542849
[TBL] [Abstract][Full Text] [Related]
31. Infliximab in the treatment of tislelizumab-induced steroid-refractory immune checkpoint inhibitor-related pneumonia: case report and literature review.
Chen Z; He J
Transl Cancer Res; 2022 Sep; 11(9):3309-3314. PubMed ID: 36237233
[TBL] [Abstract][Full Text] [Related]
32. Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse Events.
Araujo DV; Muniz TP; Yang A; Keshavarzi S; Sorotsky H; Butler MO; Saibil S; Spreafico A; Hogg D
Curr Oncol; 2021 Jun; 28(3):2173-2179. PubMed ID: 34208089
[TBL] [Abstract][Full Text] [Related]
33. Refractory Checkpoint Inhibitor Colitis Responsive to Ustekinumab.
Perez Del Nogal G; Patel N
ACG Case Rep J; 2022 Dec; 9(12):e00946. PubMed ID: 36600789
[TBL] [Abstract][Full Text] [Related]
34. Successful Treatment of Steroid-Refractory Immune Thrombocytopenia in a Patient Developing Multiple Myeloma While on Immune Checkpoint Inhibitor Therapy for Lung Cancer: A Case Report.
Hayashi Y; Tsukada M; Shinoda D; Matsui M; Iwama K; Kajiwara K; Yasuji K
J Blood Med; 2024; 15():285-290. PubMed ID: 38919949
[TBL] [Abstract][Full Text] [Related]
35. A case of steroid-resistant cystitis as an immune-related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab.
Fukunaga H; Sumii K; Kawamura S; Okuno M; Taguchi I; Kawabata G
IJU Case Rep; 2022 Nov; 5(6):521-523. PubMed ID: 36341187
[TBL] [Abstract][Full Text] [Related]
36. Mycophenolate mofetil for immune checkpoint inhibitor-related hepatotoxicity relapsing during dose reduction of corticosteroid: A report of two cases and literature review.
Ueno M; Takabatake H; Hata A; Kayahara T; Morimoto Y; Notohara K; Mizuno M
Cancer Rep (Hoboken); 2022 Sep; 5(9):e1624. PubMed ID: 35575047
[TBL] [Abstract][Full Text] [Related]
37. Coexistence of Immune Checkpoint Inhibitor-Induced Autoimmune Diabetes and Pancreatitis.
Zhang AL; Wang F; Chang LS; McDonnell ME; Min L
Front Endocrinol (Lausanne); 2021; 12():620522. PubMed ID: 33927691
[TBL] [Abstract][Full Text] [Related]
38. Successful Treatment of Steroid-Refractory Checkpoint Inhibitor Myocarditis with Globulin Derived-Therapy: A Case Report and Literature Review.
Barry T; Gallen R; Freeman C; Agasthi P; Pedrotty D; Yang M; Jokerst CE; Mookadam F; Hardaway BW; LeMond L; Arsanjani R; Larsen C
Am J Med Sci; 2021 Oct; 362(4):424-432. PubMed ID: 33974854
[TBL] [Abstract][Full Text] [Related]
39. Case Report: Nivolumab-Induced Autoimmune Pancreatitis.
Goyal P; Moyers JT; Elgohary BG; Hammami MB
J Immunother Precis Oncol; 2021 Nov; 4(4):208-211. PubMed ID: 35665025
[TBL] [Abstract][Full Text] [Related]
40. Small bowel hemorrhage from check point inhibitor enteritis: a case report.
Young K; Lin E; Chen E; Brinkerhoff B; Scott G; Yu J
BMC Gastroenterol; 2021 Sep; 21(1):345. PubMed ID: 34493214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
